Biohaven's stock surges as treatment slows progress of neurological disorder MarketWatch Sep 23, 2024 1:19pm
Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA) PR Newswire Sep 23, 2024 11:30am
Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia PR Newswire Sep 20, 2024 11:09pm
Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments PR Newswire Aug 8, 2024 8:05pm